Navigation Links
Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
Date:9/19/2012

OKLAHOMA CITY, Sept. 19, 2012 /PRNewswire/ -- Selexys Pharmaceuticals, Corp., announced today that it has successfully completed a $23 million Series A equity financing, led by MPM Capital.  Additionally, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease.  Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.

The Series A financing includes a new major investor, MPM Capital. Concurrent with the investment, Selexys also announced the addition of Todd Foley, Managing Director of MPM Capital, to the Selexys Pharmaceuticals Board of Directors.

"Patients with sickle cell disease endure great suffering and frequent hospitalization due to painful vasoocclusive crises. Chronic blockade of P-selectin function with SelG1 may improve clinical outcomes and lower the associated cost of patient care," said Dr. Scott Rollins, President and CEO of Selexys. "We are excited to welcome MPM and Novartis and look forward to a productive partnership." The combination of the Novartis agreement and the closing of the Series A financing will allow Selexys to advance the SelG1 program through a large Phase 2 clinical study in sickle cell patients and will also fund a second program at Selexys, an anti-PSGL-1 antibody, through a Phase I clinical study.

"Vasoocculsive crises represent a significant healthcare problem for sickle cell disease patients, and we were impressed by the early data for SelG1 and the quality of the Selexys team," said Todd Foley, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Selexys."

About SelG1

SelG1 is an investigatio
'/>"/>

SOURCE Selexys Pharmaceuticals, Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... A study using a relatively new imaging ... at the composition of carotid artery disease and has ... the disease, a leading cause of stroke. ... September 2010 and May 2012, was featured in the ... American College of Cardiology (JACC) Cardiovascular Interventions. Interventional ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Lilly and Company (NYSE: LLY ) today ... for more than three years was published online in ... includes summaries of previously published information; new, previously unpublished ... indicated for the treatment of osteoporosis in postmenopausal women ...
... " Two Years and Counting "   White Paper ... Milestones   and   Educational Needs Elsevier ... more than 1,300 healthcare organizations, today announced the addition of a ... its eBook, A Guide to Education and Training for ICD-10 ...
Cached Medicine Technology:Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 2Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 3Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 4Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 5Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 6Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 2Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 3
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- There,s no ... prevent type 2 diabetes, a new study says. ... vitamin D might protect people against type 2 diabetes, ... deficiency and the blood sugar disease. In this ... and vitamin D by focusing on genes that control ...
(Date:9/30/2014)... to cut climate-changing carbon emissions will reduce other ... benefits, according to a new study released today. ... options included in the final Clean Power Plan, ... premature deaths and hospitalizations, and hundreds of heart ... the new study, Health Co-benefits of Carbon Standards ...
(Date:9/30/2014)... cancer is the leading cause of cancer death in ... so many medical professionals encourage women to get mammograms, ... a minority of suspicious mammograms actually leads to a ... worry for women and their familiesnot to mention the ... and biopsies. , Recently, a different type of ...
(Date:9/30/2014)... A new study of 58 women conducted ... stress on metabolism after eating a high-fat meal equivalent to ... food restaurant, about 930 calories and 60 grams of fat. ... hour for 7 hours, conducting the study twice on each ... a stressful event in their lives during the previous 24 ...
(Date:9/30/2014)... UC Irvine immunologists reveals new information about how our ... that determines how the body,s ability to fight infection ... Immunology , neurology professor Dr. Michael Demetriou, postdoctoral scholar ... a critical mechanism underlying how T cells are created, ... cell is a type of blood cell called a ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:'Virtual breast' could improve cancer detection 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:UCI study uncovers important process for immune system development 2
... a Center for,Medicare and Medicaid Services (CMS) report ... percent of national health care spending by,2017, House ... the House to take up legislation introduced Monday ... to safeguard Medicare:, "Looking at this report, ...
... call for universal standards for new technology called IMRT ... carry out a highly refined, complex radiation treatment for ... widely from one medical center to the next than ... study raises a very large and serious problem for ...
... erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of ... legs or in the lungs) and death among patients with ... of JAMA. , The ESAs erythropoietin and darbepoetin are widely ... have indicated that there may be a higher risk of ...
... protein that stimulates blood vessel growth worsens ovarian cancer, but ... RNA wrapped in a fatty nanoparticle, a research team led ... Cancer Center reports in the Journal of the National Cancer ... target in ovarian cancer," said senior author Anil Sood, M.D., ...
... As global energy consumption rises, the ethical stakes of ... with it. , Experts from academia, business and the ... Knoxville, this April to discuss these issues and more. ... the Environment will be held April 10-12 at the ...
... Hollywood ,Stay Sane in an Insane ... ... Therapist" ( http://www.theIndustryTherapist.com ) is asking the,question why the death of Heath ... "Heath Ledger,s death is being treated with kid gloves, for instance,yet ...
Cached Medicine News:Health News:Blunt Cites New CMS Report in Calling for Action on Safeguarding Medicare 2Health News:Study Finds Variations in Doses of Radiation Therapy 2Health News:Study Finds Variations in Doses of Radiation Therapy 3Health News:Drugs used for cancer-associated anemia linked with increased risk of blood clots, death 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 3
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur. Straight....
Micro cup pituitary forceps, semi-malleable shafts....
Teardrop dissector. 90, 5 mm....
Medicine Products: